Related Experiment Video
Updated: Feb 12, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
De-escalating treatment in the adjuvant setting in HER2-positive breast cancer
Romualdo Barroso-Sousa1,2, Pedro Exman1,2, Sara M Tolaney1,2
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Abstract:
The decision to offer adjuvant therapy to patients with early-stage cancer relies on factors related to the risk of disease recurrence, degree of benefit with the proposed therapy and the associated risk of toxicities. For patients with stages II and III HER2-positive breast cancer, administering 1 year of trastuzumab plus comprehensive chemotherapy is the standard of care. However, the pivotal adjuvant trials had very few older patients and patients with small HER2-positive tumors. In this review, we will discuss the clinical data regarding strategies to de-escalate adjuvant systemic therapy in patients with early stage HER2-positive disease.
Related Concept Videos
Treatment Resistant Cancers
Position-effect Variegation
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
Position and Displacement
Serial Position Effect
Setting Time of Cement

